
Why Assigning Patents To Native American Tribes To Avoid Inter Partes Review Is Bad Medicine
Here are three big reasons why, according to IP columnist Tom Kulik.
Here are three big reasons why, according to IP columnist Tom Kulik.
If this tactic is allowed, it will be a big win for Big Pharma -- and a big loss for patients and consumers.
Discover how to gain more control over your firm’s finances and unlock smarter growth strategies—take a quick financial visibility quiz designed for law firms.